A
Anvia Therapeutics develops small molecule inhibitors targeting clinically validated pathways for inflammatory and autoimmune diseases. The company focuses on designing "superglues," a type of molecular glue, to modulate the Tumor Necrosis Factor superfamily (TNFSF) ligands. This approach aims to achieve biologic-like efficacy in treating complex immune disorders.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Anvia Therapeutics develops small molecule inhibitors targeting clinically validated pathways to treat inflammatory and autoimmune diseases. The company focuses on designing "superglues," which are molecular glues that modulate the Tumor Necrosis Factor superfamily (TNFSF) ligands. This approach aims to achieve biologic-like efficacy for patients with chronic inflammatory conditions.